Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, affecting approximately 1% of individuals aged 60 or older, with an incidence rate of 10-19 cases per 100,000 person-years.

Standard treatment for PD typically involves levodopa, which increases dopamine levels but is limited by side effects and poor brain absorption.

Non-motor symptoms, such as depression, cognitive impairment, and gastrointestinal dysfunction, affect over 80% of PD patients, complicating their overall management.

Recent research has identified six probiotic strains that may serve as adjuncts to standard PD treatment, potentially improving gut health and neurotransmitter production.

These six probiotic strains do not interfere with levodopa and are capable of producing GABA and serotonin, neurotransmitters often reduced in PD patients.

Gut health is influenced by lifestyle choices, including diet, exercise, and sleep, which are crucial for maintaining overall wellness.

To support gut health, individuals should consume a diet rich in fiber, including fruits, vegetables, and whole grains, while minimizing sugar and fat intake.

Poor sleep can negatively impact gut health and overall wellness, creating a cycle of fatigue and unhealthy choices.

Choline deficiency has been linked to exacerbating symptoms of Alzheimer's disease (AD) and increasing the risk of dementia.

AD is a leading cause of dementia worldwide, affecting over 50 million people, with prevalence rising significantly with age.

The FDA recently approved Kisunla, a drug targeting amyloid-beta plaque accumulation, marking a significant advancement in AD treatment strategies.

Despite advancements in understanding AD's mechanisms, including neuroinflammation and the role of gut microbiota, effective disease-modifying treatments remain elusive.